## AMENDMENTS TO THE CLAIMS

Please amend the claims as follows. In the amendments below, deletions are shown as ~~strikethrough~~ and additions are underlined.

1. (CURRENTLY AMENDED) A compound of formula (I)



I

wherein

Z is



in which

R is a hydrogen, a cyclic or straight-chained or branched acyclic organyl group, a lower hydroxyalkyl group, a lower aminoalkyl group, or an aralkyl or heteroaralkyl group;

n is 1;

$X_1$ is methylene, vinylene, or an NH or N(lower alkyl) group; and

$X_2$ is methylene , or, when $X_1$ is methylene or vinylene, $X_2$ is methylene or a bond; or when $X_1$ is methylene, $X_2$ is O, S, NH, or N(lower alkyl) or a bond;

$Y_1$ is methylene and $Y_2$ is methylene, vinylene, ethylene, propylene, or a bond; or

$Y_1$ is a bond and $Y_2$ is vinylene; or

$Y_1$ is ethylene and $Y_2$ is O, S, NH, or N(lower alkyl);

$Ar_1$ and $Ar_2$ independently are unsubstituted or substituted aryl or heteroaryl groups, provided that $Ar_1$ and $Ar_2$ are not simultaneously unsubstituted phenyl; and

W is oxygen; or

a pharmaceutically acceptable salt or prodrug thereof.

2. (ORIGINAL) A compound according to claim 1, wherein

$Y_1$ is methylene and $Y_2$ is a bond, methylene, ethylene, or vinylene; or

$Y_1$ is ethylene and $Y_2$ is O or S;

and

$X_1$ is methylene and $X_2$ is a bond, methylene, O, or S; or

$X_1$ is NH or N(lower alkyl) and $X_2$ is methylene.

3. (CANCELLED)

4. (PREVIOUSLY AMENDED) A compound according to claim 2, wherein $Ar_1$ and $Ar_2$ independently are mono- or disubstituted phenyl groups.

5. (ORIGINAL) A compound according to claim 4, wherein

R is a hydrogen, a lower alkyl group, a cyclic organyl group, or a substituted or unsubstituted aralkyl or heteroaralkyl group;

n is 1;

$Y_1$ is methylene, $Y_2$ is a bond, methylene, ethylene, or vinylene;

$X_1$ is methylene and $X_2$ is a bond, or.

$X_1$ is NH or N(lower alkyl) and $X_2$ is methylene; and

$Ar_1$ and $Ar_2$ are phenyl groups, independently *p*-substituted with groups selected from lower alkyl, lower alkoxy and halogen.

6. (ORIGINAL) A compound according to claim 1, having a formula (II)




II

wherein $R^N$ is hydrogen, lower alkyl, aralkyl, or heteroaralkyl;

$Ar^L$ is selected from lower alkyl, lower alkoxy and halogen

$Ar^R$ is selected from lower alkyl, lower alkoxy and halogen;

k is 1 or 2

and $A^-$ is a suitable anion.

7. (CURRENTLY AMENDED) ~~The compound according to claim 1, wherein the~~ A compound ~~is~~ selected from the group consisting of:

N-(1-(1-methylethyl)piperidin-4-yl)-N-((4-methylphenyl)methyl)-4-methoxyphenylacetamide;

N-(1-(2,2-dimethylethyl)piperidin-4-yl)-N-((4-methylphenyl)methyl)-4-methoxyphenylacetamide;

N-(1-pentylpiperidin-4-yl)-N-((4-methylphenyl)methyl)-4-methoxyphenylacetamide;

B2 N-(1-hexylpiperidin-4-yl)-N-((4-methylphenyl)methyl)-4-methoxyphenylacetamide;

N-(1-cyclohexylpiperidin-4-yl)-N-((4-methylphenyl)methyl)-4-methoxyphenylacetamide;

N-(1-cyclopentylpiperidin-4-yl)-N-((4-methylphenyl)methyl)-4-methoxyphenylacetamide;

N-(1-cyclobutylpiperidin-4-yl)-N-((4-methylphenyl)methyl)-4-methoxyphenylacetamide;

N-(1-cyclopropylpiperidin-4-yl)-N-((4-methylphenyl)methyl)-4-methoxyphenylacetamide;

N-(1-(cyclopentylmethyl)piperidin-4-yl)-N-((4-methylphenyl)methyl)-4-methoxyphenylacetamide;

N-(1-(cyclobutylmethyl)piperidin-4-yl)-N-((4-methylphenyl)methyl)-4-methoxyphenylacetamide;

N-(1-(cyclopropylmethyl)piperidin-4-yl)-N-((4-methylphenyl)methyl)-4-methoxyphenylacetamide;

N-(1-(2-hydroxyethyl)piperidin-4-yl)-N-((4-methylphenyl)methyl)-4-methoxyphenylacetamide;

N-(1-(3-hydroxypropyl)piperidin-4-yl)-N-((4-methylphenyl)methyl)-4-methoxyphenylacetamide;

*N*-((4-methylphenyl)methyl)-*N*-(piperidin-4-yl)-*N*'-phenylmethylcarbamide;

*N*-((4-methylphenyl)methyl)-*N*-(1-(2-methylpropyl)piperidin-4-yl)-*N*'-phenylmethylcarbamide;

*N*-(1-((2-bromophenyl)methyl)piperidin-4-yl)-*N*-((4-methylphenyl)methyl)-*N*'-phenylmethylcarbamide;

*N*-(1-((4-hydroxy-3-methoxyphenyl)methyl)piperidin-4-yl)-*N*-((4-methylphenyl)methyl)-*N'*-phenylmethylcarbamide;

*N*-(1-((5-ethylthien-2-yl)methyl)piperidin-4-yl)-N-((4-methylphenyl)methyl)-N'-phenylmethylcarbamide;

N-(1-(imidazol-2-ylmethyl)piperidin-4-yl)-N-((4-methylphenyl)methyl)-N'-phenylmethylcarbamide;

N-(1-(cyclohexylmethyl)piperidin-4-yl)-N-((4-methylphenyl)methyl)-N'-phenylmethylcarbamide;

N-(1-((4-fluorophenyl)methyl)piperidin-4-yl)-N-((4-methylphenyl)methyl)-N'-phenylmethylcarbamide;

B2

N-((4-methylphenyl)methyl)-N-(piperidin-4-yl)-4-methoxyphenylacetamide;

N-((4-methylphenyl)methyl)-N-(1-methylpiperidin-4-yl)-4-methoxyphenylacetamide;

N-(1-ethylpiperidin-4-yl)-N-((4-methylphenyl)methyl)-4-methoxyphenylacetamide;

N-((4-methylphenyl)methyl)-N-(1-propylpiperidin-4-yl)-4-methoxyphenylacetamide;

N-(1-butylpiperidin-4-yl)-N-((4-methylphenyl)methyl)-4-methoxyphenylacetamide;

N-(1-(3,3-dimethylbutyl)piperidin-4-yl)-N-((4-methylphenyl)methyl)-4-methoxyphenylacetamide;

*N*-(1-(cyclohexylmethyl)piperidin-4-yl)-N-((4-methylphenyl)methyl)-4-methoxyphenylacetamide;

N-((4-methylphenyl)methyl)-N-(1-(2-methylpropyl)piperidin-4-yl)-4-methoxyphenylacetamide;

N-((4-methylphenyl)methyl)-N-(1-((4-methylphenyl)methyl)piperidin-4-yl)-4-methoxyphenylacetamide;

N-(1-((4-hydroxyphenyl)methyl)piperidin-4-yl)-N-((4-methylphenyl)methyl)-4-methoxyphenylacetamide;

N-(1-((2-hydroxyphenyl)methyl)piperidin-4-yl)-N-((4-methylphenyl)methyl)-4-methoxyphenylacetamide;

N-(3-phenylpropyl)-N-(piperidin-4-yl)-4-methoxyphenylacetamide;

N-(2-phenylethyl)-N-(piperidin-4-yl)-4-methoxyphenylacetamide;

N-((2-methoxyphenyl)methyl)-N-(piperidin-4-yl)-4-methoxyphenylacetamide;

N-((2-chlorophenyl)methyl)-N-(piperidin-4-yl)-4-methoxyphenylacetamide;

N-((3,4-di-methoxyphenyl)methyl)-N-(piperidin-4-yl)-4-methoxyphenylacetamide;

N-((4-fluorophenyl)methyl)-N-(piperidin-4-yl)-4-methoxyphenylacetamide;

N-((2,4-di-chlorophenyl)methyl)-N-(piperidin-4-yl)-4-methoxyphenylacetamide;

N-((3-methylphenyl)methyl)-N-(piperidin-4-yl)-4-methoxyphenylacetamide;

N-((3-bromophenyl)methyl)-N-(piperidin-4-yl)-4-methoxyphenylacetamide;

N-(1-(phenylmethyl)piperidin-4-yl)-N-(3-phenyl-2-propen-1-yl)-4-methoxyphenylacetamide;

N-((4-methylphenyl)methyl)-N-(1-piperidin-4-yl)-phenylacetamide;

N-((4-methylphenyl)methyl)-N-(1-piperidin-4-yl)-3-phenylpropionamide;

N-((4-methylphenyl)methyl)-N-(1-piperidin-4-yl)-(phenylthio)acetamide;

N-((4-methylphenyl)methyl)-N-(1-piperidin-4-yl)-phenoxyacetamide;

N-((4-methylphenyl)methyl)-N-(1-piperidin-4-yl)-(4-chlorophenoxy)acetamide;

N-((4-methylphenyl)methyl)-N-(1-piperidin-4-yl)-3-methoxyphenylacetamide;

N-((4-methylphenyl)methyl)-N-(1-piperidin-4-yl)-4-fluorophenylacetamide;

N-((4-methylphenyl)methyl)-N-(1-piperidin-4-yl)-2,5-di-methoxyphenylacetamide;

N-((4-methylphenyl)methyl)-N-(1-piperidin-4-yl)-4-chlorophenylacetamide;

[N-((4-methylphenyl)methyl)-N-(1-(phenylmethyl)pyrrolidin-3-yl)-N'-phenylmethylcarbamide;

N-((4-methylphenyl)methyl)-N-(1-(phenylmethyl)pyrrolidin-3-yl)-4-methoxyphenylacetamide;]

2-(4-methoxyphenyl)-*N*-(4-methylbenzyl)-*N*-(piperidin-4-yl) acetamide;

2-(4-methoxyphenyl)-*N*-(4-methylbenzyl)-*N*-(1-methylpiperidin-4-yl) acetamide;

2-(4-methoxyphenyl)-*N*-(4-methylbenzyl)-*N*-(1-ethylpiperidin-4-yl) acetamide;

2-(4-methoxyphenyl)-*N*-(4-chlorbenzyl)-*N*-(1-ethylpiperidin-4-yl) acetamide.

2-(4-methoxyphenyl)-*N*-(4-chlorbenzyl)-*N*-(1-isopropylpiperidin-4-yl) acetamide;

2-(4-methoxyphenyl)-*N*-(4-chlorobenzyl)-*N*-(piperidin-4-yl) acetamide;

2-(4-methoxyphenyl)-*N*-(4-chlorbenzyl)-*N*-(1-cyclopentylpiperidin-4-yl) acetamide;

2-(4-methoxyphenyl)-*N*-(4-chlorbenzyl)-*N*-(1-isopropylpiperidin-4-yl) acetamide;

2-(phenyl)-*N*-(4-trifluoromethylbenzyl)-*N*-(1-methylpiperidin-4-yl) acetamide;

2-(4-fluorophenyl)-*N*-(4-trifluoromethylbenzyl)-*N*-(1-methylpiperidin-4-yl) acetamide;

2-(4-Methoxyphenyl)-*N*-(4-trifluoromethylbenzyl)-*N*-(1-methylpiperidin-4-yl) acetamide;

2-(4-Trifluoromethylphenyl)-*N*-(4-trifluoromethylbenzyl)-*N*-(1-methylpiperidin-4-yl) acetamide;

B2

2-(4-Fluorophenyl)-*N*-(4-fluorobenzyl)-*N*-(1-methylpiperidin-4-yl) acetamide;

2-(4-Methoxyphenyl)-*N*-(4-fluorobenzyl)-*N*-(1-methylpiperidin-4-yl) acetamide;

2-(phenyl)-*N*-(4-fluorobenzyl)-*N*-(1-methylpiperidin-4-yl) acetamide;

2-(4-Trifluoromethylphenyl)-*N*-(4-fluorobenzyl)-*N*-(1-methylpiperidin-4-yl) acetamide;

2-(4-trifluoromethylphenyl)-*N*-[4-(methoxycarbonyl)benzyl]-*N*-(1-methylpiperidin-4-yl) acetamide;

2-Phenyl-*N*-[4-(methoxycarbonyl)benzyl]-*N*-(1-methylpiperidin-4-yl) acetamide;

2-(4-Chlorophenyl)-*N*-[4-(methoxycarbonyl)benzyl]-*N*-(1-methylpiperidin-4-yl) acetamide;

2-(4-Methoxyphenyl)-*N*-[4-(methoxycarbonyl)benzyl]-*N*-(1-methylpiperidin-4-yl) acetamide;

2-(4-trifluoromethylphenyl)-*N*-[4-(methoxycarbonyl)benzyl]-*N*-(1-methylpiperidin-4-yl) acetamide;

2-Phenyl-*N*-[4-(methoxycarbonyl)benzyl]-*N*-(1-methylpiperidin-4-yl) acetamide;

2-(4-Chlorophenyl)-*N*-[4-(methoxycarbonyl)benzyl]-*N*-(1-methylpiperidin-4-yl) acetamide;

2-(4-Methoxyphenyl)-*N*-[4-(methoxycarbonyl)benzyl]-*N*-(1-methylpiperidin-4-yl) acetamide;

2-(4 methoxyphenyl)-*N*-(4-methylbenzyl)-*N*-[1-(4-chloromethyl-2-thiazolylmethyl) piperidin-4-yl] acetamide;

2-(4 methoxyphenyl)-*N*-(4-methylbenzyl)-*N*-{1-[3(1,3 dihydro-2H-benzimidazol-2-on-1-yl) propyl] piperidin-4-yl} acetamide;

2-(4-methoxyphenyl)-*N*-(2-4(fluorophenyl) ethyl)-*N*-(1-methylpiperidin-4-yl) acetamide;

2-(4-methoxyphenyl)-*N*-[2-(2,5-dimethoxyphenyl) ethyl]-*N*-(1-methylpiperidin-4-yl) acetamide;

2-(4-methoxyphenyl)-*N*-[2-(2,4-dichlorophenyl) ethyl]-*N*-(1-methylpiperidin-4-yl) acetamide;

2-(4-methoxyphenyl)-*N*-[2-(3-chlorophenyl) ethyl]-*N*-(1-methylpiperidin-4-yl) acetamide;

2-(4-methoxyphenyl)-*N*-[2-(4-methoxyphenyl) ethyl]-*N*-(1-methylpiperidin-4-yl) acetamide;

2-(4-methoxyphenyl)-*N*-[2-(3-fluorophenyl) ethyl]-*N*-(1-methylpiperidin-4-yl) acetamide;

B2

2-(4-ethoxyphenyl)-*N*-[2-(4-fluorophenethyl]-*N*-(1-methylpiperidin-4-yl) acetamide;

2-(4-ethoxyphenyl)-*N*-(4-fluorobenzyl)-*N*-(1-methylpiperidin-4-yl) acetamide;

2-(4-methoxyphenyl)-*N*-(4-methylbenzyl)-*N*-{1-[2-(2-hydroxyethoxy)ethyl] piperidin-4-yl} acetamide;

2-(4-methoxyphenyl)-*N*-(4-methylbenzyl)-*N*-[1-((2-chloro-5-thienyl)methyl) piperidin-4-yl] acetamide;

2-(4-methoxyphenyl)-*N*-(4-methylbenzyl)-*N*-[1-(2-(imidazolidinon-1-yl)ethyl)piperidin-4-yl] acetamide;

2-(4-methoxyphenyl)-*N*-(4-methylbenzyl)-*N*-{1-[2-(2,4(1H,3H)quinazolinedion-3-yl)ethyl] piperidin-4-yl} acetamide;

2-(4-methoxyphenyl)-*N*-(4-methylbenzyl)-*N*-{1-[2-(1,3-dioxolan-2-yl)ethyl]piperidin-4-yl} acetamide;

2-(4-methoxyphenyl)-*N*-(4-methylbenzyl)-*N*-{1-[2-(3-indolyl)ethyl] piperidin-4-yl} acetamide;

2-(4-methoxyphenyl)-*N*-(4-methylbenzyl)-*N*-{1-[3-(1,2,4-triazol-1-yl)propyl]piperidin-4-yl} acetamide;

2-(4-methoxyphenyl)-*N*-(4-methylbenzyl)-*N*-[1-(5-benzofurazanylmethyl)piperidin-4-yl] acetamide;

2-(4-methoxyphenyl)-*N*-(4-methylbenzyl)-*N*-[1-(5-chlorobenzo[b]thien-3-ylmethyl) piperidin-4-yl] acetamide;

2-(4-methoxyphenyl)-*N*-(4-methylbenzyl)-*N*-[1-(5-phenyl-1,2,4-oxadiazol-3-ylmethyl)piperidin-4-yl] acetamide;

2-(4-Chlorophenyl)-N-(4-methylbenzyl)-N-(1-isopropylpiperidin-4-yl)-acetamide;

2-(4-Chlorophenyl)-N-(4-methylbenzyl)-N-(1-ethylpiperidin-4-yl)-acetamide;

2-Phenyl-N-(4-methylbenzyl)-N-(1-methylpiperidin-4-yl)-acetamide[,2-(4-Chlorophenyl)-N-(4-methylbenzyl)-N-(1-methylpiperidin-4-yl)-acetamide];

2-(4-Chlorophenyl)-N-(4-methylbenzyl)-N-(1-methylpiperidin-4-yl)-acetamide;

2-(4-Chlorophenyl)-N-(4-methylbenzyl)-N-(1-cyclopentylpiperidin-4-yl)-acetamide;

2-(4-Fluorophenyl)-N-(4-methylbenzyl)-N-(1-methylpiperidin-4-yl)-acetamide;

B2 2-(4-Chlorophenyl)-N-(4-methylbenzyl)-N-(1-(2-hydroxyethyl)-piperidin-4-yl)-acetamide;

2-(4-Chlorophenyl)-N-(4-methylbenzyl)-N-(1-cyclobutylpiperidin-4-yl)-acetamide;

2-(4-Methoxyphenyl)-N-(4-methylbenzyl)-N-(1-cyclobutylpiperidin-4-yl)-acetamide[,2-(4-Methoxyphenyl)-N-(4-methylbenzyl)-N-(tropin-4-yl)-acetamide];

N-(4-Methylbenzyl)-N-(1-methylpiperidin-4-yl)-N′-benzyl-carbamide;

N-(4-Methylbenzyl)-N-(1-methylpiperidin-4-yl)-N′-phenyl-carbamide;

N-Phenethyl-N-(1-methylpiperidin-4-yl)-N′-benzyl-carbamide;

2-Phenyl-N-(4-methoxybenzyl)-N-(1-methylpiperidin-4-yl)-acetamide;

2-(4-Trifluoromethylphenyl)-N-(4-methoxybenzyl)-N-(1-methylpiperidin-4-yl)-acetamide;

2-(4-Fluorophenyl)-N-(4-methoxybenzyl)-N-(1-methylpiperidin-4-yl)-acetamide;

2-(4-Methoxyphenyl)-N-(4-methoxybenzyl)-N-(1-methylpiperidin-4-yl)-acetamide;

2-(4-Methylphenyl)-N-(4-chlorobenzyl)-N-(1-methylpiperidin-4-yl)-acetamide;

2-(4-Hydroxyphenyl)-N-(4-methylbenzyl)-N-(1-methylpiperidin-4-yl)-acetamide;

N-Phenethyl-N-(1-methylpiperidin-4-yl)-N′-phenyl-carbamide;

N-(3-Phenylpropyl)-N-(1-methylpiperidin-4-yl)-N′-benzyl-carbamide;

N-(3-Phenylpropyl)-N-(1-methylpiperidin-4-yl)-N′-phenyl-carbamide;

2-(4-Methoxyphenyl)-2,2-ethylene-N-(4-methylbenzyl)-N-(1-methylpiperidin-4-yl) acetamide;

2-(4-Methoxyphenyl)-N-alpha-methylbenzyl-N-(1-methylpiperidin-4-yl) acetamide;

[2-(4-Methoxyphenyl)-N-(4-methylbenzyl)-N-(3-tropen-4-yl) acetamide;]

2-Phenyl-2-ethyl-N-(4-methylbenzyl)-N-(1-methylpiperidin-4-yl) acetamide;

N-Phenethyl-N-(4-methylbenzyl)-N-(1-methylpiperidin-4-yl)-amine;

2-(4-Methoxyphenyl)-N-(1-indanyl)-N-(1-methylpiperidin-4-yl) acetamide;

N-(4-Methylbenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-methoxybenzyl)-carbamide;

2-(3,4-dimethoxyphenyl)-N-(4-methylbenzyl)-N-(1-methylpiperidin-4-yl) acetamide;

B2 2-(3,4-Methylenedioxyphenyl)-N-(4-methylbenzyl)-N-(1-methylpiperidin-4-yl) acetamide;

2-(4-Methoxyphenyl)-N-(4-methylbenzyl)-N-(1-t-butylpiperidin-4-yl)-acetamide;

N-(4-Methylbenzyl)-N-(1-methylpiperidin-4-yl)-N′-phenethyl-carbamide;

N-Phenethyl-N-(1-methylpiperidin-4-yl)-N′-phenethyl-carbamide;

N-(4-Methylbenzyl)-N-(1-t-butylpiperidin-4-yl)-N′-(4-methoxybenzyl)-carbamide;

2-(4-Ethoxyphenyl)-N-(4-methylbenzyl)-N-(1-methylpiperidin-4-yl) acetamide;

2-(4-Butoxyphenyl)-N-(4-methylbenzyl)-N-(1-methylpiperidin-4-yl) acetamide;

2-(4-i-Propoxyphenyl)-N-(4-methylbenzyl)-N-(1-methylpiperidin-4-yl) acetamide;

2-(4-t-Butoxyphenyl)-N-(4-methylbenzyl)-N-(1-methylpiperidin-4-yl) acetamide;

2-(4-Butoxyphenyl)-N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl) acetamide;

2-(4-Propoxyphenyl)-N-(4-flourobenzyl)-N-(1-methylpiperidin-4-yl) acetamide;

2-(4-i-Propoxyphenyl)-N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl) acetamide; and

2-(4-t-Butoxyphenyl)-N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl) acetamide.

8. (PREVIOIUSLY AMENDED) A compound of formula (I)




I

wherein

Z is



in which

R is a hydrogen, a cyclic or straight-chained or branched acyclic organyl group, a lower hydroxyalkyl group, a lower aminoalkyl group, or an aralkyl or heteroaralkyl group; and

n is 1;

$X_1$ is methylene, vinylene, or an NH or N(lower alkyl) group; and

$X_2$ is methylene, or, when $X_1$ is methylene or vinylene, $X_2$ is methylene or a bond; or when $X_1$ is methylene, $X_2$ is O, S, NH, or N(lower alkyl) or a bond;

$Y_1$ is methylene and $Y_2$ is methylene, vinylene, ethylene, propylene, or a bond; or

$Y_1$ is a bond and $Y_2$ is vinylene; or

$Y_1$ is ethylene and $Y_2$ is O, S, NH, or N(lower alkyl);

$Ar_1$ and $Ar_2$ are different unsubstituted or substituted aryl or heteroaryl groups; and

W is oxygen; or

a pharmaceutically acceptable salt or prodrug thereof.

9. (ORIGINAL) A compound according to claim 8, wherein

$Y_1$ is methylene and $Y_2$ is a bond, methylene, ethylene, or vinylene; or

$Y_1$ is ethylene and $Y_2$ is O or S; and

$X_1$ is methylene and $X_2$ is a bond, methylene, O, or S; or

$X_1$ is NH or N(lower alkyl) and $X_2$ is a methylene .

10. (CANCELLED)

11. (PREVIOUSLY AMENDED) A compound according to claim 9, wherein $Ar_1$ and $Ar_2$ independently are mono- or disubstituted phenyl groups.

12. (PREVIOUSLY AMENDED) A compound according to claim 11, wherein

R is a hydrogen, a lower alkyl group, a cyclic organyl group, or an, optionally substituted, alalkyl or heteroaralkyl group;

$Y_1$ is methylene, $Y_2$ is a bond, methylene, ethylene, or vinylene;

$X_1$ is methylene and $X_2$ is a bond, or

$X_1$ is NH or N(lower alkyl) and $X_2$ is methylene; and

$Ar_1$ and $Ar_2$ are phenyl groups, independently p-substituted with groups selected from alkyl, lower alkoxy and halogen.

13. (PREVIOUSLY AMENDED) A compound according to claim 8, having a formula (II):



II

wherein $R^N$ is hydrogen, lower alkyl, aralkyl, or heteroaralkyl;

$Ar^L$ is selected from lower alkyl, lower alkoxy and halogen

$Ar^R$ is selected from lower alkyl, lower alkoxy and halogen;

k is 1 or 2

and $A^-$ is a suitable anion.

14. (PREVIOUSLY AMENDED) A pharmaceutical composition comprising an effective amount of a compound of formula (I):



I

wherein

Z is



in which

R is a hydrogen, a cyclic or straight-chained or branched acyclic organyl group, a lower hydroxyalkyl group, a lower aminoalkyl group, or an aralkyl or heteroaralkyl group; and

n is 1;

$X_1$ is methylene, vinylene, or an NH or N(lower alkyl) group; and

$X_2$ is methylene, or, when $X_1$ is methylene or vinylene, $X_2$ is methylene or a bond; or when $X_1$ is methylene, $X_2$ is O, S, NH, or N(lower alkyl) or a bond;

$Y_1$ is methylene and $Y_2$ is methylene, vinylene, ethylene, propylene, or a bond; or

$Y_1$ is a bond and $Y_2$ is vinylene; or

$Y_1$ is ethylene and $Y_2$ is O, S, NH, or N(lower alkyl);

$Ar_1$ and $Ar_2$ independently are unsubstituted or substituted aryl or heteroaryl groups, provided that $Ar_1$ and $Ar_2$ are not simultaneously phenyl; and

W is oxygen;

or a pharmaceutically acceptable salt or prodrug thereof, and

a pharmaceutically acceptable diluent or excipient.

15. (ORIGINAL) A method of inhibiting an activity of a monoamine receptor comprising contacting the monoamine receptor or a system containing the monoamine receptor with an amount of one or more of the compounds of claim 1 that is effective in inhibiting the activity of the monoamine receptor.

16. (ORIGINAL) The method of claim 15 wherein the monoamine receptor is a serotonin receptor.

17. (ORIGINAL) The method of claim 16 wherein the serotonin receptor is the 5-HT2A subclass.

18. (ORIGINAL) The method of claim 16 wherein the serotonin receptor is in the central nervous system.

19. (ORIGINAL) The method of claim 16 wherein the serotonin receptor is in the peripheral nervous system.

20. (ORIGINAL) The method of claim 16 wherein the serotonin receptor is in blood cells or platelets.

21. (ORIGINAL) The method of claim 16 wherein the serotonin receptor is mutated or modified.

22. (ORIGINAL) The method of claim 15 wherein the activity is signaling activity.

23. (ORIGINAL) The method of claim 15 wherein the activity is constitutive.

24. (ORIGINAL) The method of claim 15 wherein the activity is associated with serotonin receptor activation.

25. (ORIGINAL) A method of inhibiting an activation of a monoamine receptor comprising contacting the monoamine receptor or a system containing the monoamine receptor with an amount of a compound of one or more of the compounds of claim 1 that is effective in inhibiting the activation of the monoamine receptor.

26. (ORIGINAL) The method of claim 25 wherein the activation is by an agonistic agent.

27. (ORIGINAL) The method of claim 26 wherein the agonistic agent is exogenous.

28. (ORIGINAL) The method of claim 26 wherein the agonistic agent is endogenous.

29. (ORIGINAL) The method of claim 25 wherein the activation is constitutive.

30. (ORIGINAL) The method of claim 25 wherein the monoamine receptor is a serotonin receptor.

31. (ORIGINAL) The method of claim 30 wherein the serotonin receptor is the 5-HT2A subclass.

32. (ORIGINAL) The method of claim 30 wherein the serotonin receptor is in the central nervous system.

33. (ORIGINAL) The method of claim 30 wherein the serotonin receptor is in the peripheral nervous system.

34. (ORIGINAL) The method of claim 30 wherein the serotonin receptor is in blood cells or platelets.

35. (ORIGINAL) The method of claim 30 wherein the serotonin receptor is mutated or modified.

36. (ORIGINAL) A method of treating a disease condition associated with a monoamine receptor comprising administering to a subject in need of such treatment a therapeutically effective amount of one or more of the compounds of claim 1.

37. (ORIGINAL) The method of claim 36 wherein the disease condition is selected from the group consisting of schizophrenia, psychosis, migraine, hypertension, thrombosis, vasospasm, ischemia, depression, anxiety, sleep disorders and appetite disorders.

38. (ORIGINAL) The method of claim 36 wherein the disease condition is associated with dysfunction of a monoamine receptor.

39. (ORIGINAL) The method of claim 36 wherein the disease condition is associated with activation of a monoamine receptor.

40. (ORIGINAL) The method of claim 36 wherein the disease condition is associated with increased activity of monoamine receptor.

41. (ORIGINAL) The method of claim 36 wherein the monoamine receptor is a serotonin receptor

42. (ORIGINAL) The method of claim 41 wherein the serotonin receptor is the 5-HT2A subclass.

43. (ORIGINAL) The method of claim 41 wherein the serotonin receptor is in the central nervous system.

44. (ORIGINAL) The method of claim 41 wherein the serotonin receptor is in the peripheral nervous system.

45. (ORIGINAL) The method of claim 41 wherein the serotonin receptor is in blood cells or platelets.

46. (ORIGINAL) The method of claim 41 wherein the serotonin receptor is mutated or modified.

47. (ORIGINAL) A method of treating schizophrenia comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of one or more of the compounds of claim 1.

48. (ORIGINAL) A method of treating migraine comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of one or more of the compounds of claim 1.

49. (ORIGINAL) A method of treating psychosis comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of one or more of the compounds of claim 1.

50 – 52. (CANCELLED)

53. (PREVIOUSLY ADDED) A method according to claim 49 wherein the psychosis is a drug-induced psychosis.